Whole-exome sequencing and imaging genetics identify functional variants for rate of change in hippocampal volume in mild cognitive impairment

Molecular Psychiatry

Volumn 18, Issue 7, 2013, Pages 781-787

  Nho, K ^a   Corneveaux, J J ^b   Kim, S ^a   Lin, H ^a   Risacher, S L ^a   Shen, L ^a   Swaminathan, S ^a   Ramanan, V K ^a   Liu, Y ^a   Foroud, T ^a   Inlow, M H ^c   Siniard, A L ^b   Reiman, R A ^b   Aisen, P S ^d   Petersen, R C ^e   Green, R C ^f   Jack, C R ^e   Weiner, M W ^g,h   Baldwin, C T ⁱ   Lunetta, K ^j   Farrer, L A ⁱ   Furney, S J ^k,l   Lovestone, S ^k,l   Simmons, A ^k,l   Mecocci, P ^m   Vellas, B ⁿ   Tsolaki, M ^o   Kloszewska, I ^p   Soininen, H ^q   McDonald, B C ^a   Farlow, M R ^a   Ghetti, B ^a   Huentelman, M J ^b   Saykin, A J ^a   more..

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^c ROSE HULMAN INSTITUTE OF TECHNOLOGY   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e MAYO CLINIC   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

ⁱ BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j BOSTON UNIVERSITY   (United States)

^k KING'S COLLEGE LONDON   (United Kingdom)

^l King s College London   (United Kingdom)

^m UNIVERSITY OF PERUGIA   (Italy)

ⁿ TOULOUSE UNIVERSITY HOSPITAL   (France)

^o ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^p MEDICAL UNIVERSITY OF LODZ   (Poland)

^q KUOPIO UNIVERSITY HOSPITAL   (Finland)

more..

Author keywords

ADNI; CARD10; imaging genetics; mild cognitive impairment; PARP1; whole exome sequencing

Indexed keywords

APOLIPOPROTEIN E3; CARD10 PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PEPTIDES AND PROTEINS; UNCLASSIFIED DRUG;

ARTICLE; BRAIN SIZE; COMPUTER MODEL; EXOME; GENE MAPPING; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC RISK; GENETIC VARIABILITY; HIPPOCAMPUS; HUMAN; META ANALYSIS (TOPIC); MILD COGNITIVE IMPAIRMENT; NERVE DEGENERATION; NEUROIMAGING; PRIORITY JOURNAL; QUANTITATIVE TRAIT; SINGLE NUCLEOTIDE POLYMORPHISM; WHOLE EXOME SEQUENCING;

ALZHEIMER DISEASE; APOLIPOPROTEIN E3; ATROPHY; CARD SIGNALING ADAPTOR PROTEINS; COHORT STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; EXOME; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HIPPOCAMPUS; HUMANS; MALE; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; POLY(ADP-RIBOSE) POLYMERASES; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84879420878     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2013.24     Document Type: Article

References (75)

1. Thies W, Bleiler L 2011Alzheimer's disease facts and figures. Alzheimers Dement 2011; 7: 208-244.
2. Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet 2006; 368: 387-403.
3. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297: 353-356.
4. Bergem AL. Heredity in dementia of the Alzheimer type. Clin Genet 1994; 46(1 Spec No): 144-149.
5. Bergem AL, Engedal K, Kringlen E. The role of heredity in late-onset Alzheimer disease and vascular dementia. A twin study. Arch Gen Psychiatry 1997; 54: 264-270.
6. Gatz M, Pedersen NL, Berg S, Johansson B, Johansson K, Mortimer JA et al. Her-itability for Alzheimer's disease: the study of dementia in Swedish twins. J Ger-ontol A Biol Sci Med Sci 1997; 52: M117-M125.
7. Bertram L, Tanzi RE. Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses. Nat Rev Neurosci 2008; 9: 768-778.
8. Abraham R, Moskvina V, Sims R, Hollingworth P, Morgan A, Georgieva L et al. A genome-wide association study for late-onset Alzheimer's disease using DNA pooling. BMC Med Genomics 2008; 1: 44.
9. Beecham GW, Martin ER, Li YJ, Slifer MA, Gilbert JR, Haines JL et al. Genome-wide association study implicates a chromosome 12 risk locus for late-onset Alzheimer disease. Am J Hum Genet 2009; 84: 35-43.
10. Bertram L, Lange C, Mullin K, Parkinson M, Hsiao M, Hogan MF et al. Genome-wide association analysis reveals putative Alzheimer's disease susceptibility loci in addition to APOE. Am J Hum Genet 2008; 83: 623-632.
11. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 2009; 41: 1088-1093.
12. Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 2009; 41: 1094-1099.
13. Jun G, Naj AC, Beecham GW, Wang LS, Buros J, Gallins PJ et al. Meta-analysis confirms CR1, CLU, and PICALM as alzheimer disease risk loci and reveals interactions with APOE genotypes. Arch Neurol 2010; 67: 1473-1484.
14. Seshadri S, Fitzpatrick AL, Ikram MA, DeStefano AL, Gudnason V, Boada M et al. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA 2010; 303: 1832-1840.
15. Naj AC, Jun G, Beecham GW, Wang LS, Vardarajan BN, Buros J et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet 2011; 43: 436-441.
16. Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet 2011; 43: 429-435.
17. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993; 261: 921-923.
18. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 1997; 278: 1349-1356.
19. Bu G, Apolipoprotein E. and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat Rev Neurosci 2009; 10: 333-344.
20. So HC, Gui AH, Cherny SS, Sham PC. Evaluating the heritability explained by known susceptibility variants: a survey of ten complex diseases. Genet Epidemiol 2011; 35: 310-317.
21. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ et al. Finding the missing heritability of complex diseases. Nature 2009; 461: 747-753.
22. Cirulli ET, Goldstein DB. Uncovering the roles of rare variants in common disease through whole-genome sequencing. Nat Rev Genet 2010; 11: 415-425.
23. Cooper GM, Shendure J. Needles in stacks of needles: finding disease-causal variants in a wealth of genomic data. Nat Rev Genet 2011; 12: 628-640.
24. Ng SB, Buckingham KJ, Lee C, Bigham AW, Tabor HK, Dent KM et al. Exome sequencing identifies the cause of a mendelian disorder. Nat Genet 2010; 42: 30-35.
25. Holm H, Gudbjartsson DF, Sulem P, Masson G, Helgadottir HT, Zanon C et al. A rare variant in MYH6 is associated with high risk of sick sinus syndrome. Nat Genet 2011; 43: 316-320.
26. Choi M, Scholl UI, Ji W, Liu T, Tikhonova IR, Zumbo P et al. Genetic diagnosis by whole exome capture and massively parallel DNA sequencing. Proc Natl Acad Sci USA 2009; 106: 19096-19101.
27. Klein CJ, Botuyan MV, Wu Y, Ward CJ, Nicholson GA, Hammans S et al. Mutations in DNMT1 cause hereditary sensory neuropathy with dementia and hearing loss. Nat Genet 2011; 43: 595-600.
28. Kim JJ, Park YM, Baik KH, Choi HY, Yang GS, Koh I et al. Exome sequencing and subsequent association studies identify five amino acid-altering variants influencing human height. Human Genet 2012; 131: 471-478.
29. Pottier C, Hannequin D, Coutant S, Rovelet-Lecrux A, Wallon D, Rousseau S et al. High frequency of potentially pathogenic SORL1 mutations in autosomal dominant early-onset Alzheimer disease. Mol Psychiatry 2012; 17: 875-879.
30. Guerreiro RJ, Lohmann E, Kinsella E, Bras JM, Luu N, Gurunlian N et al. Exome sequencing reveals an unexpected genetic cause of disease: NOTCH3 mutation in a Turkish family with Alzheimer's disease. Neurobiol Aging 2012; 33: 1008 e1017-1008 e1023.
31. Bettens K, Brouwers N, Engelborghs S, Lambert JC, Rogaeva E, Vandenberghe R et al. Both common variations and rare non-synonymous substitutions and small insertion/deletions in CLU are associated with increased Alzheimer risk. Mol Neurodegener 2012; 7: 3.
32. Ferrari R, Moreno JH, Minhajuddin AT, O'Bryant SE, Reisch JS, Barber RC et al. Implication of common and disease specific variants in CLU, CR1, and PICALM. Neurobiol Aging 2012; 33: 1846.
33. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999; 56: 303-308.
34. Petersen RC, Roberts RO, Knopman DS, Boeve BF, Geda YE, Ivnik RJ et al. Mild cognitive impairment: ten years later. Arch Neurol 2009; 66: 1447-1455.
35. Saykin AJ, Shen L, Foroud TM, Potkin SG, Swaminathan S, Kim S et al. Alzheimer's Disease Neuroimaging Initiative biomarkers as quantitative phenotypes: genetics core aims, progress, and plans. Alzheimer's Dement 2010; 6: 265-273.
36. Kim S, Swaminathan S, Shen L, Risacher SL, Nho K, Foroud T et al. Genome-wide association study of CSF biomarkers Abeta1-42, t-tau, and p-tau181p in the ADNI cohort. Neurology 2011; 76: 69-79.
37. Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC et al. The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement 2012; 8(1 Suppl): S1-68.
38. Risacher SL, Shen L, West JD, Kim S, McDonald BC, Beckett LA et al. Longitudinal MRI atrophy biomarkers: relationship to conversion in the ADNI cohort. Neurobiol Aging 2010; 31: 1401-1418.
39. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 2009; 25: 1754-1760.
40. DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet 2011; 43: 491-498.
41. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 2010; 38: e164.
42. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P et al. A method and server for predicting damaging missense mutations. Nat Meth 2010; 7: 248-249.
43. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 2009; 4: 1073-1081.
44. Risacher SL, Saykin AJ, West JD, Shen L, Firpi HA, McDonald BC. Baseline MRI predictors of conversion from MCI to probable AD in the ADNI cohort. Curr Alzheimer Res 2009; 6: 347-361.
45. Jack Jr. CR, Bernstein MA, Fox NC, Thompson P, Alexander G, Harvey D et al. The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging 2008; 27: 685-691.
46. Ashburner J, Friston KJ. Voxel-based morphometry-the methods. NeuroImage 2000; 11(6 Pt 1): 805-821.
47. Brand K, Eisele T, Kreusel U, Page M, Page S, Haas M et al. Dysregulation of monocytic nuclear factor-kappa B by oxidized low-density lipoprotein. Arterioscler Thromb Vasc Biol 1997; 17: 1901-1909.
48. Muller JM, Krauss B, Kaltschmidt C, Baeuerle PA, Rupec RA. Hypoxia induces c-fos transcription via a mitogen-activated protein kinase-dependent pathway. J Biol Chem 1997; 272: 23435-23439.
49. Barnes LL, Wilson RS, Li Y, Gilley DW, Bennett DA, Evans DA. Change in cognitive function in Alzheimer's disease in African-American and white persons. Neuro-epidemiology 2006; 26: 16-22.
50. Barnes J, Scahill RI, Schott JM, Frost C, Rossor MN, Fox NC. Does Alzheimer's disease affect hippocampal asymmetry? Evidence from a cross-sectional and longitudinal volumetric MRI study. Dement Geriatr Cogn Disord 2005; 19: 338-344.
51. Howie BN, Donnelly P, Marchini J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet 2009; 5: e1000529.
52. Scahill RI, Schott JM, Stevens JM, Rossor MN, Fox NC. Mapping the evolution of regional atrophy in Alzheimer's disease: unbiased analysis of fluid-registered serial MRI. Proc Natl Acad Sci USA 2002; 99: 4703-4707.
53. McAllister-Lucas LM, Inohara N, Lucas PC, Ruland J, Benito A, Li Q et al. Bimp1, a MAGUK family member linking protein kinase C activation to Bcl10-mediated NF-kappaB induction. J Biol Chem 2001; 276: 30589-30597.
54. Jones AR, Overly CC, Sunkin SM. The Allen Brain Atlas: 5 years and beyond. Nat Rev Neurosci 2009; 10: 821-828.
55. Wang L, Guo Y, Huang WJ, Ke X, Poyet JL, Manji GA et al. Card10 is a novel caspase recruitment domain/membrane-associated guanylate kinase family member that interacts with BCL10 and activates NF-kappa B. J Biol Chem 2001; 276: 21405-21409.
56. Wegener E, Krappmann D. CARD-Bcl10-Malt1 signalosomes: missing link to NF-kappaB. Science's STKE 2007; 2007: pe21.
57. McAllister-Lucas LM, Jin X, Gu S, Siu K, McDonnell S, Ruland J et al. The CARMA3-Bcl10-MALT1 signalosome promotes angiotensin II-dependent vascular inflammation and atherogenesis. J Biol Chem 2010; 285: 25880-25884.
58. Sun J. CARMA3: A novel scaffold protein in regulation of NF-kappaB activation and diseases. World J Biol Chemistry 2010; 1: 353-361.
59. Kaltschmidt B, Uherek M, Volk B, Baeuerle PA, Kaltschmidt C. Transcription factor NF-kappaB is activated in primary neurons by amyloid beta peptides and in neurons surrounding early plaques from patients with Alzheimer disease. Proc Natl Acad Sci USA 1997; 94: 2642-2647.
60. Ruland J, Duncan GS, Elia A, del Barco Barrantes I, Nguyen L, Plyte S et al. Bcl10 is a positive regulator of antigen receptor-induced activation of NF-kappaB and neural tube closure. Cell 2001; 104: 33-42.
61. Strosznajder JB, Czapski GA, Adamczyk A, Strosznajder RP. Poly(ADP-ribose) polymerase-1 in amyloid beta toxicity and Alzheimer's disease. Mol Neurobiol 2012; 46: 78-84.
62. Moncada S, Bolanos JP. Nitric oxide, cell bioenergetics and neurodegeneration. J Neurochem 2006; 97: 1676-1689.
63. Strosznajder RP, Jesko H, Zambrzycka A. Poly(ADP-ribose) polymerase: the nuclear target in signal transduction and its role in brain ischemia-reperfusion injury. Mol Neurobiol 2005; 31: 149-167.
64. Menissier de Murcia J, Ricoul M, Tartier L, Niedergang C, Huber A, Dantzer F et al. Functional interaction between PARP-1 and PARP-2 in chromosome stability and embryonic development in mouse. EMBO J 2003; 22: 2255-2263.
65. Yu SW, Andrabi SA, Wang H, Kim NS, Poirier GG, Dawson TM et al. Apoptosis-inducing factor mediates poly(ADP-ribose) (PAR) polymer-induced cell death. Proc Natl Acad Sci USA 2006; 103: 18314-18319.
66. Ba X, Garg NJ. Signaling mechanism of poly(ADP-ribose) polymerase-1 (PARP-1) in inflammatory diseases. Am J Pathol 2011; 178: 946-955.
67. Liu HP, Lin WY, Wu BT, Liu SH, Wang WF, Tsai CH et al. Evaluation of the poly(ADP-ribose) polymerase-1 gene variants in Alzheimer's disease. J Clin Lab Anal 2010; 24: 182-186.
68. Goldberg S, Visochek L, Giladi E, Gozes I, Cohen-Armon M. PolyADP-ribosylation is required for long-term memory formation in mammals. J Neurochem 2009; 111: 72-79.
69. Cohen-Armon M, Visochek L, Katzoff A, Levitan D, Susswein AJ, Klein R et al. Long-term memory requires polyADP-ribosylation. Science 2004; 304: 1820-1822.
70. Love S, Barber R, Wilcock GK. Increased poly(ADP-ribosyl)ation of nuclear proteins in Alzheimer's disease. Brain 1999; 122(Pt 2): 247-253.
71. Abeti R, Abramov AY, Duchen MR. Beta-amyloid activates PARP causing astrocytic metabolic failure and neuronal death. Brain 2011; 134(Pt 6): 1658-1672.
72. Kauppinen TM. Multiple roles for poly(ADP-ribose)polymerase-1 in neurological disease. Neurochem Int 2007; 50: 954-958.
73. Kauppinen TM, Swanson RA. The role of poly(ADP-ribose) polymerase-1 in CNS disease. Neuroscience 2007; 145: 1267-1272.
74. Infante J, Llorca J, Mateo I, Rodriguez-Rodriguez E, Sanchez-Quintana C, Sanchez-Juan P et al. Interaction between poly(ADP-ribose) polymerase 1 and interleukin 1A genes is associated with Alzheimer's disease risk. Dement Geriatr Cogn Disord 2007; 23: 215-218.
75. Kauppinen TM, Suh SW, Higashi Y, Berman AE, Escartin C, Won SJ et al. Poly(ADP-ribose)polymerase-1 modulates microglial responses to amyloid beta. J Neuroinfl 2011; 8: 152.